Jazz Pharmaceuticals plc Buyback
OLI recorded this information on 12/10/2018
Company:
Jazz Pharmaceuticals plc
Buyback:
JAZZ buyback
$Amount Authorized:
$400,000,000
Buyback Details:
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and other factors.
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
JAZZ SEC Filing Email Alerts Service
Open the JAZZ Page at The Online Investor »
|
||||||||||||||||||||||||
Open the JAZZ Page at The Online Investor (in a new window) »
 Free JAZZ Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.44 out of 4) 54th percentile
(ranked higher than approx. 54% of all stocks covered)
Analysts' Target Price: JAZZ Stock Forecast Based on Zacks ABR data; powered by Xignite |
